Ascendis Pharma A/S (NASDAQ:ASND) Short Interest Update

Ascendis Pharma A/S (NASDAQ:ASND) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 3,770,000 shares, a growth of 5.6% from the November 15th total of 3,570,000 shares. Based on an average trading volume of 587,700 shares, the short-interest ratio is currently 6.4 days.

Institutional Trading of Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently made changes to their positions in ASND. Groupama Asset Managment purchased a new stake in Ascendis Pharma A/S in the third quarter valued at about $60,000. Janus Henderson Group PLC raised its position in shares of Ascendis Pharma A/S by 6.8% in the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after purchasing an additional 267,881 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP grew its position in Ascendis Pharma A/S by 3.4% during the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after purchasing an additional 155,971 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. Citigroup raised their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Bank of America upped their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research note on Monday, September 23rd. Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Stock Down 0.6 %

NASDAQ:ASND opened at $129.87 on Monday. The firm has a 50 day moving average of $129.15 and a 200 day moving average of $132.72. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00. The stock has a market capitalization of $7.88 billion, a price-to-earnings ratio of -16.07 and a beta of 0.67.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.